Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1978 ARTÍCULOS , VIENDO DEL 436 AL 450

An update on Alzheimer's disease: Immunotherapeutic agents, stem cell therapy and gene editing

Patwardhan AG, Belemkar S.

Life Sci. 2021 Oct 1;282:119790. doi: 10.1016/j.lfs.2021.119790. Epub 2021 Jul 8.

Defective mitophagy and synaptic degeneration in Alzheimer's disease: Focus on aging, mitochondria and synapse

Morton H, Kshirsagar S, Orlov E, Bunquin LE, Sawant N, Boleng L, George M, Basu T, Ramasubramanian B, Pradeepkiran JA, Kumar S, Vijayan M, Reddy AP, Reddy PH.

Free Radic Biol Med. 2021 Aug 20;172:652-667. doi: 10.1016/j.freeradbiomed.2021.07.013. Epub 2021 Jul 8.

NM101 Phase III study of NE3107 in Alzheimer's disease: rationale, design and therapeutic modulation of neuroinflammation and insulin resistance

Reading CL, Ahlem CN, Murphy MF.

Neurodegener Dis Manag. 2021 Aug;11(4):289-298. doi: 10.2217/nmt-2021-0022. Epub 2021 Jul 12.

The Trial to Reduce Antimicrobial Use in Nursing Home Residents With Alzheimer Disease and Other Dementias (TRAIN-AD): A Cluster Randomized Clinical Trial

Mitchell SL, D'Agata EMC, Hanson LC, Loizeau AJ, Habtemariam DA, Tsai T, Anderson RA, Shaffer ML.

JAMA Intern Med. 2021 Sep 1;181(9):1174-1182. doi: 10.1001/jamainternmed.2021.3098.

Mirrored-Self Misidentification in a Patient With Probable Alzheimer Dementia

Fernandes C, Taveira I, Nzwalo H.

JAMA Neurol. 2021 Sep 1;78(9):1150. doi: 10.1001/jamaneurol.2021.2142.

The Current State of Pharma and the FDA: Approval of a Dementia Drug as a Case in Point

Eiser AR.

Am J Med. 2021 Dec;134(12):1442-1443. doi: 10.1016/j.amjmed.2021.06.014. Epub 2021 Jul 12.

Gut dysbiosis, insulin resistance and Alzheimer's disease: review of a novel approach to neurodegeneration

Lazar E, Sherzai A, Adeghate J, Sherzai D.

Front Biosci (Schol Ed). 2021 Jun 30;13(1):17-29. doi: 10.52586/S550.

FDA Approval of Aduhelm Paves a New Path for Alzheimer's Disease

Tanzi RE.

ACS Chem Neurosci. 2021 Aug 4;12(15):2714-2715. doi: 10.1021/acschemneuro.1c00394. Epub 2021 Jul 14.

Feasibility of improving strength and functioning and decreasing the risk of falls in older adults with Alzheimer's dementia: a randomized controlled home-based exercise trial

Cezar NOC, Ansai JH, Oliveira MPB, da Silva DCP, Gomes WL, Barreiros BA, Langelli TCO, de Andrade LP.

Arch Gerontol Geriatr. 2021 Sep-Oct;96:104476. doi: 10.1016/j.archger.2021.104476. Epub 2021 Jul 4.

Aducanumab for Alzheimer's disease: expediting approval and delaying science

Salinas RA.

BMJ Evid Based Med. 2021 Oct;26(5):214-215. doi: 10.1136/bmjebm-2021-111765. Epub 2021 Jul 14.

NMDA and AMPA receptors dysregulation in Alzheimer's disease

Babaei P.

Eur J Pharmacol. 2021 Oct 5;908:174310. doi: 10.1016/j.ejphar.2021.174310. Epub 2021 Jul 12.

Cholinergic neurodegeneration in Alzheimer disease mouse models

Shekari A, Fahnestock M.

Handb Clin Neurol. 2021;182:191-209. doi: 10.1016/B978-0-12-819973-2.00013-7.

Chronic traumatic encephalopathy and the nucleus basalis of Meynert

Mufson EJ, Kelley C, Perez SE.

Handb Clin Neurol. 2021;182:9-29. doi: 10.1016/B978-0-12-819973-2.00002-2.

Resilience and Resistance in Aging and Alzheimer Disease: Another Step to Fill the Gap Between Clinicians and Researchers

Poggesi A.

Neurology. 2021 Sep 7;97(10):465-466. doi: 10.1212/WNL.0000000000012500. Epub 2021 Jul 15.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias